Fostering collaborations and the career of a newly recruited pulmonary scientist

促进新聘肺科科学家的合作和职业生涯

• 批准号: 7936154
• 负责人: RICHARD J MARTIN
• 金额: $ 71.94万
• 依托单位: NATIONAL JEWISH HEALTH
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7936154
• 关键词: Address; Adverse effects; Advisory Committees; American; Architecture; Area; Arts; Asthma; Award; Basic Science; Biology; California; Cancer Grant Supplements (P30); Candidate Disease Gene; Caring; Cells; Clinical; Clinical Medicine; Collaborations; Commit; Communities; Community Health; Core Facility; Critical Care; Development; Disease; Doctor of Philosophy; Drug usage; Ensure; Environment; Epithelial Cells; Equilibrium; Evaluation; Faculty; Fostering; Funding; Gene Expression; Gene Expression Profiling; Genes; Glucocorticoid Receptor; Glucocorticoids; Goals; Health; Human Resources; Immune; Internal Medicine; Investigation; Investments; Laboratories; Libraries; Life; Lung; Lung diseases; Manuscripts; Mediating; Medicine; Methods; Modeling; Molecular; Mus; Pathway interactions; Patients; Physicians; Publications; Receptor Signaling; Recruitment Activity; Reporter; Research; Research Infrastructure; Research Personnel; Research Proposals; Resistance; San Francisco; Scientist; Signal Pathway; Signal Transduction; Small Interfering RNA; Therapeutic; Tissues; Training; Universities; Washington; Work; base; career; career development; cell type; clinical practice; direct patient care; falls; follower of religion Jewish; improved; innovation; interest; meetings; member; programs; promoter; success; tool

DESCRIPTION (provided by applicant): The long-term goal of National Jewish Health (NJH) is to improve the lives of patients with lung disease both through direct patient care, and a synergistic combination of clinical, translational and basic research. The general strategy is to recruit physicians and scientists that focus on lung disease and biology, and to foster strong collaborations. Specifically, last fall, NJH undertook a national search for a physician-scientist with an outstanding research background and an interest in airway biology and disease. As a result of this effort, the Pulmonary Division successfully recruited an outstanding, newly independent physician-scientist to join the faculty and conduct research on glucocorticoid signaling. Dr. Anthony Gerber received his MD/Ph.D. at the University of Washington in 1998, and completed his training at the University of California, San Francisco in 2004. He has recently developed an exciting research program on tissue and promoter specific mechanisms of glucocorticoid signaling. This is an area with significant relevance to airway biology and the goals of NJH. Glucocorticoids are among the most widely used drugs in clinical medicine and are central in the treatment of asthma and other immune-mediated diseases. However, severe side effects and resistance complicate their use in clinical practice. A key issue in glucocorticoid receptor (GR) biology and pulmonary therapeutics is to understand the beneficial and harmful effects of glucocorticoid signaling, in particular cell types within the lung, and to define the molecular mechanisms that control these activities. State-of-the-art multiplexed methods to analyze gene expression will be used to address this research area, methods that are broadly applicable to the study of lung disease. With the funds from the PSO award Dr. Gerber's research programs on glucocorticoid signaling will be advanced, collaborations on disease modifying pathways in the lung and multiplexed analysis of gene expression will be facilitated. This will be accomplished by (1) investments in infrastructure for Dr. Gerber's lab and employing skilled personnel to assist with his investigations, (2) integrating tools and methods for multiplexed gene expression analysis into the investigations of other researchers in the division/core, and (3) forming a committee to oversee Dr. Gerber's progress. NJH is at the forefront of the treatment and research of lung and immune-mediated diseases, which afflict millions of Americans. This project will advance the understanding of glucocorticoid signaling, which is central in the treatment of many diseases. It will also foster collaborations among a group of outstanding scientists focused on lung disease.

描述（由申请人提供）：国家犹太人健康（NJH）的长期目标是通过直接患者护理改善肺部疾病患者的生活，以及临床，转化和基础研究的协同结合。一般策略是招募专注于肺部疾病和生物学的医师和科学家，并促进强有力的合作。具体来说，去年秋天，NJH对具有出色研究背景的医师科学家进行了全国范围的搜索，并对气道生物学和疾病感兴趣。由于这项工作，肺部划分成功地招募了一名新的独立的医师科学家，以加入教职员工，并进行有关糖皮质激素信号传导的研究。安东尼·格伯（Anthony Gerber）博士获得了医学博士/博士学位。 1998年，在华盛顿大学，并于2004年在加利福尼亚大学旧金山大学完成了培训。这是与气道生物学和NJH目标有很大相关性的领域。糖皮质激素是临床医学中使用最广泛的药物之一，在治疗哮喘和其他免疫介导的疾病中是中心的。但是，严重的副作用和抵抗使它们在临床实践中的使用变得复杂。糖皮质激素受体（GR）生物学和肺疗法的关键问题是了解糖皮质激素信号传导的有益和有害作用，特别是肺内的细胞类型，并定义控制这些活性的分子机制。分析基因表达的最先进的多路复用方法将用于解决该研究领域，这些方法广泛适用于肺部疾病研究。随着PSO奖Gerber博士的糖皮质激素信号研究计划的资金，将提前进行有关疾病修改途径的合作，并将促进基因表达的多路复用分析。这将通过（1）Gerber博士实验室的基础设施进行投资，并雇用熟练的人员来协助他的调查，（2）整合了多元基因表达分析的工具和方法，以纳入部门/核心中其他研究人员的调查，以及（3）组建一个委员会来谴责Gerber博士的进步。 NJH处于肺部和免疫介导的疾病的治疗和研究的最前沿，这使数百万美国人受苦。该项目将提高对糖皮质激素信号传导的理解，这在许多疾病的治疗中至关重要。它还将促进一群专注于肺部疾病的杰出科学家。

项目成果

Vitamin D and asthma: another dimension.

维生素 D 和哮喘：另一个层面。

• DOI: 10.1164/rccm.201109-1737ed
• 发表时间: 2011
• 期刊: American journal of respiratory and critical care medicine
• 影响因子: 24.7
• 作者: Gerber,AnthonyN;Sutherland,ERand
• 通讯作者: Sutherland,ERand